Response to Neratinib and Xeloda Combo Seen in Breast Cancer Patients with Brain Metastasis

Response to Neratinib and Xeloda Combo Seen in Breast Cancer Patients with Brain Metastasis
Combining Puma Biotechnology’s candidate therapy PB272, also known as neratinib, with the chemotherapy drug Xeloda (capecitabine) appears to have therapeutic potential for patients with advanced HER2-positive breast cancer and brain metastasis, who were not previously treated with Tykerb (lapatinib), a clinical study reports. Results from the ongoing, multicenter Phase 2 trial (NCT01494662) found this combo therapy effectively shrank metastatic brain tumors in nearly half of treated patients, and did so with tolerable toxicity. These positive results support further research into the use of neratinib to treat breast cancer patients with brain metastases. The findings were featured in an oral presentation, “TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM),” given at the recent 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentation is also available on Puma's website. “As a small molecule that can cross the blood brain barrier, neratinib potentially offers patients with HER2-positive metastatic breast cancer that has metastasized to the CNS a novel HER2 targeted treatment option,” Alan Auerbach, CEO and pr
Subscribe or to access all post and page content.